Improvement of immunogenic chemotherapy by STAT3 inhibition

Heng Yang, Takahiro Yamazaki, Federico Pietrocola, Heng Zhou, Laurence Zitvogel, Yuting Ma, Guido Kroemer

    Research output: Contribution to journalArticlepeer-review

    14 Citations (Scopus)

    Abstract

    The inhibition of STAT3 may exert cell-autonomous cytotoxic and cytostatic effects, yet may also stimulate anticancer immunosurveillance through the neutralization of immunosuppressive circuitries. In addition, STAT3 inhibition in cancer cells may stimulate the type 1 interferon response elicited by anthracyclines. This pathway results in an enhanced chemotherapy-associated anticancer immune response with improved therapeutic efficacy. Hence, combination therapies that include immunogenic cell death (ICD) inducers and STAT3 inhibitors can be envisaged.

    Original languageEnglish
    JournalOncoImmunology
    Volume5
    Issue number2
    DOIs
    Publication statusPublished - 1 Feb 2016

    Cite this